Clinical applications of angiogenic growth factors and their inhibitors - PubMed (original) (raw)

Review

. 1999 Dec;5(12):1359-64.

doi: 10.1038/70928.

Affiliations

• PMID: 10581076
• DOI: 10.1038/70928

Review

Clinical applications of angiogenic growth factors and their inhibitors

N Ferrara et al. Nat Med. 1999 Dec.

Abstract

Promoting the formation of new collateral vessels in ischemic tissues using angiogenic growth factors (therapeutic angiogenesis) is a an exciting frontier of cardiovascular medicine. Conversely, inhibition of the action of key regulators of angiogenesis, such as VEGF, constitutes a promising approach for the treatment of solid tumors and intraocular neovascular syndromes. These concepts are being tested now in clinical trials.

PubMed Disclaimer

Similar articles

• Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
  Wood JM. Wood JM. Medicina (B Aires). 2000;60 Suppl 2:41-7. Medicina (B Aires). 2000. PMID: 11188930
• Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF).
  Baumgartner I, Isner JM. Baumgartner I, et al. Vasa. 1998 Nov;27(4):201-6. Vasa. 1998. PMID: 9859738 Review.
• The biology of VEGF and its receptors.
  Ferrara N, Gerber HP, LeCouter J. Ferrara N, et al. Nat Med. 2003 Jun;9(6):669-76. doi: 10.1038/nm0603-669. Nat Med. 2003. PMID: 12778165 Review.
• [Vascular endothelial growth factor VEGF stimulates angiogenesis in good and bad situations].
  Heits F, Wiedemann GJ, Jelkmann W. Heits F, et al. Dtsch Med Wochenschr. 1998 Feb 27;123(9):259-65. doi: 10.1055/s-2007-1023947. Dtsch Med Wochenschr. 1998. PMID: 9524537 Review. German. No abstract available.

Cited by

• Rho activity critically and selectively regulates endothelial cell organization during angiogenesis.
  Hoang MV, Whelan MC, Senger DR. Hoang MV, et al. Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1874-9. doi: 10.1073/pnas.0308525100. Epub 2004 Feb 9. Proc Natl Acad Sci U S A. 2004. PMID: 14769914 Free PMC article.
• Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma.
  Le Jan S, Amy C, Cazes A, Monnot C, Lamandé N, Favier J, Philippe J, Sibony M, Gasc JM, Corvol P, Germain S. Le Jan S, et al. Am J Pathol. 2003 May;162(5):1521-8. doi: 10.1016/S0002-9440(10)64285-X. Am J Pathol. 2003. PMID: 12707035 Free PMC article.
• VEGF-Trap: a VEGF blocker with potent antitumor effects.
  Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. Holash J, et al. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8. doi: 10.1073/pnas.172398299. Epub 2002 Aug 12. Proc Natl Acad Sci U S A. 2002. PMID: 12177445 Free PMC article.
• Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
  Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, Kuwai T, Abbruzzese JL, Fidler IJ. Yokoi K, et al. Cancer Res. 2005 Nov 15;65(22):10371-80. doi: 10.1158/0008-5472.CAN-05-1698. Cancer Res. 2005. PMID: 16288027 Free PMC article.
• Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
  Sasaki T, Kitadai Y, Nakamura T, Kim JS, Tsan RZ, Kuwai T, Langley RR, Fan D, Kim SJ, Fidler IJ. Sasaki T, et al. Neoplasia. 2007 Dec;9(12):1066-77. doi: 10.1593/neo.07667. Neoplasia. 2007. PMID: 18084614 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)